ESSA Pharma Inc. (EPIX): Price and Financial Metrics

ESSA Pharma Inc. (EPIX): $5.37

0.74 (+15.98%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add EPIX to Watchlist
Sign Up

EPIX Price/Volume Stats

Current price $5.37 52-week high $11.67
Prev. close $4.63 52-week low $2.58
Day low $4.59 Volume 65,000
Day high $5.39 Avg. volume 112,883
50-day MA $6.46 Dividend yield N/A
200-day MA $6.31 Market Cap 238.23M

EPIX Stock Price Chart Interactive Chart >


ESSA Pharma Inc. (EPIX) Company Bio


ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor. The company was founded in 2009 and is based in Vancouver, Canada.


EPIX Latest News Stream


Event/Time News Detail
Loading, please wait...

EPIX Latest Social Stream


Loading social stream, please wait...

View Full EPIX Social Stream

Latest EPIX News From Around the Web

Below are the latest news stories about ESSA PHARMA INC that investors may wish to consider to help them evaluate EPIX as an investment opportunity.

These Stocks under $10 Are Poised To Explode

In this piece, we will take a look at these stocks under $10 are poised to explode. If you want to skip our introduction to these tricky stocks, jump to These 5 Stocks Under $10 Are Poised To Explode. The US equity markets remain on track for a strong finish in 2023 as major indices […]

Yahoo | December 21, 2023

EPIX: Initial Data from Combination Trial of Masofaniten and Enzalutamide Expected in 2024…

By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Update on Masofaniten Clinical Programs ESSA Pharma Inc. (NASDAQ:EPIX) is developing masofaniten (EPI-7386), its next-generation antigen molecule that is designed to target the N-terminal domain (NTD) of the androgen receptor (AR) as a treatment for prostate cancer. Masofaniten is currently being evaluated in two

Yahoo | December 20, 2023

EPIX Stock Earnings: ESSA Pharma Beats EPS for Q4 2023

EPIX stock results show that ESSA Pharma beat analyst estimates for earnings per share the fourth quarter of 2023.

InvestorPlace Earnings on InvestorPlace | December 12, 2023

ESSA Pharma Inc (EPIX) Reports Fiscal Q4 and Full-Year Earnings, Advances in Prostate Cancer ...

Corporate Update and Financial Highlights for the Year Ended September 30, 2023

Yahoo | December 12, 2023

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023

ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company, focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fourth quarter and fiscal year ended September 30, 2023.

Yahoo | December 12, 2023

Read More 'EPIX' Stories Here

EPIX Price Returns

1-mo -5.79%
3-mo -42.26%
6-mo -11.97%
1-year 68.34%
3-year -80.27%
5-year 133.01%
YTD -18.64%
2023 161.90%
2022 -82.25%
2021 19.03%
2020 116.91%
2019 161.90%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!